RB1 Genetic Alterations in Estrogen Receptor–Positive Breast Carcinomas: Correlation With Neuroendocrine Differentiation
- 17 June 2024
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 37 (8) , 100541
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P30-CA008748, P50 CA24779 01)
- National Institutes of Health
- eFFECTOR Therapeutics
- AstraZeneca
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- Cycle for Survival
- Goldman Sachs
- Breast Cancer Research Foundation
This publication has 35 references indexed in Scilit:
- Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database studyBreast Cancer Research and Treatment, 2023
- Novel insights into RB1 mutationCancer Letters, 2022
- Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organsHuman Pathology, 2018
- A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patientsBreast Cancer Research and Treatment, 2018
- Biology and evolution of poorly differentiated neuroendocrine tumorsNature Medicine, 2017
- Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%Laboratory Investigation, 2017
- Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lungBreast Cancer Research and Treatment, 2016
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special typeLaboratory Investigation, 2009